
Patrick K Campbell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3448125/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery, 2016, 6, 154-165.	9.4	372
2	Loss of Â-tubulin polyglutamylation in ROSA22 mice is associated with abnormal targeting of KIF1A and modulated synaptic function. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3213-3218.	7.1	202
3	CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCHâ€associated neurodegeneration and mass lesions. Cancer, 2018, 124, 2607-2620.	4.1	73
4	Mutation of a Novel Gene Results in Abnormal Development of Spermatid Flagella, Loss of Intermale Aggression and Reduced Body Fat in Mice. Genetics, 2002, 162, 307-320.	2.9	64
5	Utility of Early Screening Magnetic Resonance Imaging for Extensive Hip Osteonecrosis in Pediatric Patients Treated With Glucocorticoids. Journal of Clinical Oncology, 2015, 33, 610-615.	1.6	56
6	Clofarabine salvage therapy for refractory highâ€risk langerhans cell histiocytosis. Pediatric Blood and Cancer, 2013, 60, E19-22.	1.5	34
7	Neuroinflammatory Disease as an Isolated Manifestation of Hemophagocytic Lymphohistiocytosis. Journal of Clinical Immunology, 2020, 40, 901-916.	3.8	33
8	The Role of Leukapheresis in the Current Management of Hyperleukocytosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia. Pediatric Blood and Cancer, 2016, 63, 1546-1551.	1.5	29
9	Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia. Cancer, 2013, 119, 2061-2066.	4.1	27
10	Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1277-1303.	4.9	26
11	Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia. Leukemia Research, 2011, 35, 1321-1329.	0.8	21
12	Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase. Cancer Chemotherapy and Pharmacology, 2014, 73, 1307-1313.	2.3	20
13	Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	19
14	Hemophagocytic Lymphohistiocytosis and Progressive Disseminated Histoplasmosis. Emerging Infectious Diseases, 2016, 22, 1119-1121.	4.3	14
15	Optimizing Drug-Drug Interaction Alerts Using a Multidimensional Approach. Pediatrics, 2019, 143, .	2.1	14
16	Dasatinib induces a dramatic response in a child with refractory juvenile xanthogranuloma with a novel MRC1-PDGFRB fusion. Blood Advances, 2020, 4, 2991-2995.	5.2	10
17	Development of BRAFV600E-positive acute myeloid leukemia in a patient on long-term dabrafenib for multisystem LCH. Blood Advances, 2022, , .	5.2	5
18	Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies. Cancer, 2021, 127, 2074-2082.	4.1	2

PATRICK K CAMPBELL

#	Article	IF	CITATIONS
19	Clinical Outcomes and Molecular Responses in Children with Langerhans Cell Histiocytosis Treated with MAPK Pathway Inhibitors. Blood, 2018, 132, 3684-3684.	1.4	2
20	Haemophagocytic lymphohistiocytosis restricted to the central nervous system. Archives of Disease in Childhood, 2021, 106, 527-527.	1.9	1
21	a Phase I Trial of Bendamustine in Combination with Clofarabine and Etoposide in Pediatric Patients with Relapsed or Refractory Hematologic Malignancies. Blood, 2016, 128, 1628-1628.	1.4	1
22	Unraveling the Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms through Whole Exome Sequencing. Blood, 2014, 124, 1887-1887.	1.4	1
23	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Blood, 2015, 126, 481-481.	1.4	0